Investorideas.com – big ideas for global investors Search www.investorideas.com
   Member Access       Sign-up       Newsfeeds        Companies        Stock Directories       Research       Video       Funding   




Category: Investment, Biotech, Biodefense

OTC Biotech News; Aethlon Medical (OTC: AEMD) Announces Biotech Showcase 2012 Presentation

Ideas get bigger when you share them...

Visit this company: www.aethlonmedical.com

SAN DIEGO - January 4, 2012 (Investorideas.com newswire) – OTC Biotech News alert; Aethlon Medical, Inc. (OTCBB: AEMD), the the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, reports that its Chairman and CEO James A. Joyce will be the lead-off presenter at the Biotech Showcase™ 2012. Mr. Joyce's presentation will begin at 9:00 am Pacific Time on January 9th , 2012. A live webcast of the presentation will be available at: http://www.media-server.com/m/p/dfvbu2du

About Biotech Showcase™

Investorideas.com Newswire

Biotech Showcase™ is a forum devoted to providing biotechnology companies, investors and pharmaceutical executives with an opportunity to meet in one place during the course of one of the world's largest annual healthcare conferences that attracts investors and biopharmaceutical executives from around the world.

Now in its fourth year, this rapidly growing financial-focused biotech conference features multiple tracks of presenting companies, plenary sessions, an opportunity to schedule one-to-one partnering meetings and networking. The attendees to the showcase include private and public equity investors, analysts, bankers, biopharmaceutical industry executives and other industry professionals. The event is being held at the Parc 55 Wyndham San Francisco – Union Square.

About Aethlon Medical

The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.

Contacts:

James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com

John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com

Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs

Free News Alerts
Email:  

Read more News





TOP

Investor Ideas © 2000 - 2014 InvestorIdeas.com®, ECON

Sign up here

login | logout | about us | contact | disclaimer / disclosure |
advertise | company profile directory | partners / links |
job search | privacy policy | trade | services | sitemap |